Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses advancements in breast cancer treatment, highlighting CDK4/6 inhibitors and ...

The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.

EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Saturday, October 19, 202 ...

The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.

On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...

Novartis on Friday announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...

In the last four days, Divi's Lab share price has surged 13 per cent after global brokerage firm Citi initiated coverage on ...

This is a news collection page for Darwin. Check this page for latest news headlines covering major stories, events from Darwin and surrounding Northern Territory. Get breaking news faster than ...

The FDA also approved a ribociclib and letrozole co-pack for the same indication Atezolizumab and hyaluronidase-tqjs for subcutaneous injection, for all adult indications, as the intravenous ...